These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19348555)

  • 1. Seasonal influenza vaccines: evolutions and future trends.
    Monto AS; Ohmit SE
    Expert Rev Vaccines; 2009 Apr; 8(4):383-9. PubMed ID: 19348555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Aug; 7(6):713-9. PubMed ID: 18665769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging data on the safety and efficacy of influenza vaccines in children.
    Vesikari T
    Pediatr Infect Dis J; 2008 Nov; 27(11 Suppl):S159-61. PubMed ID: 18955892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 May; 58(19):521-4. PubMed ID: 19478718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza control in the 21st century: Optimizing protection of older adults.
    Monto AS; Ansaldi F; Aspinall R; McElhaney JE; Montaño LF; Nichol KL; Puig-Barberà J; Schmitt J; Stephenson I
    Vaccine; 2009 Aug; 27(37):5043-53. PubMed ID: 19559118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seasonal influenza vaccinations: specialized products for different target groups.
    Monto AS
    Vaccine; 2010 Sep; 28 Suppl 4():D14-23. PubMed ID: 20713256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.
    Beran J; Vesikari T; Wertzova V; Karvonen A; Honegr K; Lindblad N; Van Belle P; Peeters M; Innis BL; Devaster JM
    J Infect Dis; 2009 Dec; 200(12):1861-9. PubMed ID: 19909082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Nov; 58(44):1241-5. PubMed ID: 19910912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
    Collin N; de Radiguès X;
    Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned: role of influenza vaccine production, distribution, supply, and demand--what it means for the provider.
    Orenstein WA; Schaffner W
    Am J Med; 2008 Jul; 121(7 Suppl 2):S22-7. PubMed ID: 18589064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
    Vellozzi C; Burwen DR; Dobardzic A; Ball R; Walton K; Haber P
    Vaccine; 2009 Mar; 27(15):2114-20. PubMed ID: 19356614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M2e-based universal influenza A vaccine.
    Fiers W; De Filette M; El Bakkouri K; Schepens B; Roose K; Schotsaert M; Birkett A; Saelens X
    Vaccine; 2009 Oct; 27(45):6280-3. PubMed ID: 19840661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on influenza A (H1N1) 2009 monovalent vaccines.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Oct; 58(39):1100-1. PubMed ID: 19816398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza virus-like particle vaccines.
    Haynes JR
    Expert Rev Vaccines; 2009 Apr; 8(4):435-45. PubMed ID: 19348559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.